IMRX
Price
$3.53
Change
+$0.34 (+10.66%)
Updated
Jun 27 closing price
Capitalization
127.03M
37 days until earnings call
LSB
Price
$0.92
Change
-$0.02 (-2.13%)
Updated
Jun 27 closing price
Capitalization
17.53M
Interact to see
Advertisement

IMRX vs LSB

Header iconIMRX vs LSB Comparison
Open Charts IMRX vs LSBBanner chart's image
Immuneering
Price$3.53
Change+$0.34 (+10.66%)
Volume$2.76M
Capitalization127.03M
LakeShore Biopharma
Price$0.92
Change-$0.02 (-2.13%)
Volume$12.48K
Capitalization17.53M
IMRX vs LSB Comparison Chart in %
Loading...
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMRX vs. LSB commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRX is a Buy and LSB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (IMRX: $3.53 vs. LSB: $0.92)
Brand notoriety: IMRX and LSB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMRX: 205% vs. LSB: 71%
Market capitalization -- IMRX: $127.03M vs. LSB: $17.53M
IMRX [@Biotechnology] is valued at $127.03M. LSB’s [@Biotechnology] market capitalization is $17.53M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMRX’s FA Score shows that 0 FA rating(s) are green whileLSB’s FA Score has 1 green FA rating(s).

  • IMRX’s FA Score: 0 green, 5 red.
  • LSB’s FA Score: 1 green, 4 red.
According to our system of comparison, both IMRX and LSB are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMRX’s TA Score shows that 5 TA indicator(s) are bullish while LSB’s TA Score has 3 bullish TA indicator(s).

  • IMRX’s TA Score: 5 bullish, 4 bearish.
  • LSB’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, IMRX is a better buy in the short-term than LSB.

Price Growth

IMRX (@Biotechnology) experienced а +37.89% price change this week, while LSB (@Biotechnology) price change was -6.23% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

IMRX is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMRX($127M) has a higher market cap than LSB($17.5M). IMRX YTD gains are higher at: 60.455 vs. LSB (-73.441). IMRX has higher annual earnings (EBITDA): -63.85M vs. LSB (-220.1M). LSB has more cash in the bank: 49.5M vs. IMRX (35.9M). IMRX has less debt than LSB: IMRX (4.08M) vs LSB (369M). LSB has higher revenues than IMRX: LSB (672M) vs IMRX (0).
IMRXLSBIMRX / LSB
Capitalization127M17.5M726%
EBITDA-63.85M-220.1M29%
Gain YTD60.455-73.441-82%
P/E RatioN/AN/A-
Revenue0672M-
Total Cash35.9M49.5M73%
Total Debt4.08M369M1%
TECHNICAL ANALYSIS
Technical Analysis
IMRXLSB
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
55%
MACD
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
87%
N/A
Declines
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 3 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
Aroon
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
IMRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SACH1.180.08
+7.27%
Sachem Capital Corp
SFBS79.070.47
+0.60%
ServisFirst Bancshares
MCVT1.86N/A
N/A
Mill City Ventures III Ltd
RYAAY56.99-0.32
-0.56%
Ryanair Holdings plc
AVXL9.48-0.09
-0.94%
Anavex Life Sciences Corp

IMRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with NUVL. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMRX
1D Price
Change %
IMRX100%
+10.66%
NUVL - IMRX
37%
Loosely correlated
+0.68%
SRRK - IMRX
31%
Poorly correlated
+0.93%
ENTBF - IMRX
31%
Poorly correlated
+12.13%
INSM - IMRX
30%
Poorly correlated
-5.11%
VTYX - IMRX
29%
Poorly correlated
-4.29%
More

LSB and

Correlation & Price change

A.I.dvisor indicates that over the last year, LSB has been loosely correlated with GLTO. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LSB jumps, then GLTO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LSB
1D Price
Change %
LSB100%
-2.76%
GLTO - LSB
34%
Loosely correlated
-2.29%
APM - LSB
26%
Poorly correlated
-1.87%
VIVS - LSB
24%
Poorly correlated
+2.11%
GOVX - LSB
21%
Poorly correlated
+1.04%
IMRX - LSB
20%
Poorly correlated
+10.66%
More